The startup develops tissue-based drug screening technologies utilizing microfluidic systems to create three-dimensional cancer and immuno-oncology models. This platform enables pharmaceutical and biotechnology professionals to perform high-throughput drug screening with predictive, animal-free disease models, significantly lowering costs and accelerating the drug discovery timeline.
Funding
$290K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug screening methods often rely on animal models or simplified 2D cell cultures, which fail to accurately replicate the complex microenvironment of human tumors. This leads to poor prediction of drug efficacy in clinical trials and high failure rates in drug development. Furthermore, screening with limited amounts of patient-derived tissue is challenging.
Solution
ScreenIn3D offers a microfluidic-based platform for tissue-based drug screening, utilizing 3D cancer and immuno-oncology models to provide a more physiologically relevant environment. Their UpScale3D technology enables high-throughput screening with miniaturized, patient-derived 3D explants, including tumoroids, multicellular spheroids, and organoids. The platform supports co-culture models with immune cells and allows for customization of cell types, assay duration, and readouts. By mimicking the in vivo components that mediate drug mechanisms of action, ScreenIn3D provides data with greater predictive value of drug efficacy in human studies, facilitating rapid decision-making in preclinical drug discovery and development. The system enables a high number of replicates even when dealing with very small patient-derived samples, resulting in greater statistical significance.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies involved in drug discovery and development, particularly those focused on oncology and immuno-oncology, as well as researchers seeking more predictive preclinical screening models.
Features
- Proprietary UpScale3D microfluidic lab-on-a-chip technology for creating 3D cancer models.
- Hydrostatic pressure-driven system for formation and culture of hundreds of 3D cancer models in a miniaturized format.
- Capability to use customer-provided cell models or source them through ScreenIn3D's biorepository.
- Customizable assays for cell types, assay duration, and readouts.
- Support for mono-culture and complex in vitro models, including co-cultures with immune cells.
- Single-compound or combination (chemo-combo or radio-chemo combo) screening.
- Automated software for assessment of tumoroid readouts using custom image analysis tools.
- Retrieval of 3D cancer models after treatment for tissue post-processing and characterization.
- Supernatant collection for analysis of cytokines or metabolites.